You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
以嶺藥業(002603.SZ):收到半夏白朮天麻顆粒的受理通知書

格隆匯7月10日丨以嶺藥業(002603.SZ)公佈,公司於2025年7月9日收到國家藥品監督管理局覈準簽發的半夏白朮天麻顆粒的《受理通知書》。半夏白朮天麻顆粒是公司申報註冊的第一個經典名方品種,品種處方爲國家中醫藥管理局2018年4月發佈的《古代經典名方目錄(第一批)》中的第81首處方,出自清代程國彭《醫學心悟》,其功能主治爲:化痰熄風,健脾祛溼。用於風痰上擾證。症見眩暈,頭痛,胸膈痞悶,噁心嘔吐,舌苔白膩,脈弦滑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account